A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease.

Pavine L C LefevreParambir S DulaiZhongya WangLeonardo GuizzettiBrian G FeaganAnca PopMohamed YassineLisa M ShackeltonVipul JairathWilliam J SandbornNiels Vande Casteele

Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2021)

Patients who are predicted to have accelerated baseline CZP clearance are at risk of subtherapeutic CZP concentrations. Patient-level probabilities for a composite remission outcome can be predicted for patients with CD by entering commonly available patient- and disease-related factors into an online CDST ( https://premedibd.com ) incorporating predicted CZP clearance.

Keyphrases

end stage renal disease
case report
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
systemic lupus erythematosus
disease activity
ulcerative colitis